多发性骨髓瘤患者克隆性造血、肿瘤标志物及结局的种族和民族差异
本研究纳入495例多发性骨髓瘤患者(西班牙裔45例、非西班牙裔黑人52例、非西班牙裔白人398例),比较人口学、临床和分子特征。西班牙裔和非西班牙裔黑人发病年龄早于非西班牙裔白人(53岁和57岁 vs 63岁,P < .001)。非西班牙裔黑人总生存优于非西班牙裔白人(HR,0.50;95% CI,0.31-0.81;P = .005),校正临床特征后关联减弱(HR,0.62;95% CI,0.37-1.03;P = .06)。
要点
- 西班牙裔和非西班牙裔黑人骨髓瘤发病年龄早于非西班牙裔白人。
- 非西班牙裔黑人接受造血细胞移植时间较非西班牙裔白人更长(376天 vs 248天;P = .01)。
- 克隆性造血见于12%患者,与非西班牙裔黑人较差总生存相关(HR,4.36;95% CI,1.36-14.00)。
核心结论
- 本研究揭示可能驱动接受可比治疗的多发性骨髓瘤患者临床差异的分子特征差异,并新颖地纳入西班牙裔个体。
研究设计与样本
- 研究纳入495例多发性骨髓瘤患者,自我报告西班牙裔45例、非西班牙裔黑人52例、非西班牙裔白人398例。
主要发现
- 西班牙裔和非西班牙裔黑人发病年龄早于非西班牙裔白人(53岁和57岁 vs 63岁,P < .001)。
- 不同种族和民族组治疗无差异,但非西班牙裔黑人接受造血细胞移植时间长于非西班牙裔白人(376天 vs 248天;P = .01)。
- 非西班牙裔黑人总生存优于非西班牙裔白人(HR,0.50;95% CI,0.31-0.81;P = .005),校正临床特征后关联减弱(HR,0.62;95% CI,0.37-1.03;P = .06)。
- IRF4肿瘤突变在西班牙裔患者中最常见,SP140、AUTS2和SETD2突变在非西班牙裔黑人患者中最常见。
- 观察到BCL7A、SPEF2和ANKRD26肿瘤表达按种族和民族存在差异;克隆性造血见于12%患者,与非西班牙裔黑人无克隆性造血患者相比总生存较差(HR,4.36;95% CI,1.36-14.00)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) incidence, mortality, and survival vary by race and ethnicity, but the causes of differences remain unclear. We investigated demographic, clinical, and molecular features of diverse MM patients to elucidate mechanisms driving clinical disparities. This study included 495 MM patients (self-reported Hispanic, n = 45; non-Hispanic Black, n = 52; non-Hispanic White, n = 398). Hispanic and non-Hispanic Black individuals had an earlier age of onset than non-Hispanic White individuals (53 and 57 vs 63 years, respectively, P < .001). There were no differences in treatment by race and ethnicity groups, but non-Hispanic Black patients had a longer time to hematopoietic cell transplant than non-Hispanic White patients (376 days vs 248 days; P = .01). Overall survival (OS) was improved for non-Hispanic Black compared with non-Hispanic White patients (HR, 0.50; 95% CI, 0.31-0.81; P = .005), although this association was attenuated after adjusting for clinical features (HR, 0.62; 95% CI, 0.37-1.03; P = .06). Tumor mutations in IRF4 were most common in Hispanic patients, and mutations in SP140, AUTS2, and SETD2 were most common in non-Hispanic Black patients. Differences in tumor expression of BCL7A, SPEF2, and ANKRD26 by race and ethnicity were observed. Clonal hematopoiesis was detected in 12% of patients and associated with inferior OS in non-Hispanic Black patients compared with patients without clonal hematopoiesis (HR, 4.36; 95% CI, 1.36-14.00). This study provides insight into differences in molecular features that may drive clinical disparities in MM patients receiving comparable treatment, with the novel inclusion of Hispanic individuals.
引用
- Peres LC, Colin-Leitzinger CM, Teng M, et al. Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma. Blood Adv. 2022. PMID: 35500227. doi:10.1182/bloodadvances.2021006652
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。